Nucleus Biologics launches AI-driven, custom media formulation platform

By The Science Advisory Board staff writers

February 9, 2021 -- Nucleus Biologics has launched its artificial intelligence (AI) research platform, NB-AIR, for optimizing cell culture formulations for cell and gene therapies.

The platform is based on AI algorithms and allows scientists to create optimized formulas based on meta-analysis of peer-reviewed articles. NB-AIR, initially targeted for cell therapy developers, provides peer-tested compounds and formula recommendations based on cell type and critical quality attributes. The AI-guided formulations will improve performance of cell therapy and shorten the development time of the therapies, according to the firm.

The use of in vitro cell culture media has a well-documented effect on cell quality and therapeutic efficacy. Previously, researchers had to rely on suppliers who sell proprietary media formulation with little ability to modify the media for their specific needs.

"We are democratizing formulations enabling scientists to tap into the collective knowledge of their peers, become experts quickly and own their media formulation." said David Sheehan, founder, president, and chief executive officer of Nucleus Biologics.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.